ArticleFrontiers in oncology2022
Mutant-Allele Tumor Heterogeneity, a Favorable Biomarker to Assess Intra-Tumor Heterogeneity, in Advanced Lung Adenocarcinoma.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Tumor Mutational Burden and Clinical Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy.Cancer research communications · 2026Article
- Impact of preanalytical factors on liquid biopsy in the canine cancer model.Communications medicine · 2026Article
- Comprehensive analysis of zinc finger protein 367 as a potential pan-cancer diagnostic and prognostic biomarker and underlying biological mechanisms.Discover oncology · 2025Article
- Novel Resistance Mechanisms to Second-Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC.Genes, chromosomes & cancer · 2025Article
- PGLS as an immune and prognostic biomarker: from pan-cancer analysis to validation.Discover oncology · 2025Article
- The value of nucleoporin 188 in diagnosis, prognosis and immunoregulation: from pan-cancer analysis to gastric cancer verification.Frontiers in immunology · 2025Article
- Comprehensive Pan-Cancer Analysis Identifies IGFL1 as an Oncogenic Biomarker and Immunotherapeutic Target with Experimental Validation in Bladder Cancer.International journal of general medicine · 2025Article
- Impact of preanalytical factors on liquid biopsy in the canine cancer model.bioRxiv : the preprint server for biology · 2024Article
- Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer.Scientific reports · 2024Article
- CCDC58 is a potential biomarker for diagnosis, prognosis, immunity, and genomic heterogeneity in pan-cancer.Scientific reports · 2024Article
- The Potential Value of RPS27A in Prognosis and Immunotherapy: From Pan-Cancer Analysis to Hepatocellular Carcinoma Validation.ImmunoTargets and therapy · 2024Article
- Fatty acid metabolism prognostic signature predicts tumor immune microenvironment and immunotherapy, and identifies tumorigenic role of MOGAT2 in lung adenocarcinoma.Frontiers in immunology · 2024Article
- Mutant-allele dispersion correlates with prognosis risk in patients with advanced non-small cell lung cancer.Journal of cancer research and clinical oncology · 2023Article
- Genomic and Glycolytic Entropy Are Reliable Radiogenomic Heterogeneity Biomarkers for Non-Small Cell Lung Cancer.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intra-tumor heterogeneity (ITH) plays a vital role in drug resistance and recurrence of lung cancer. We used a mutant-allele tumor heterogeneity (MATH) algorithm to assess ITH and investigated its association with clinical and molecular features in advanced lung adenocarcinoma. Methods: Tissues from 63 patients with advanced lung adenocarcinoma were analyzed by next-generation sequencing (NGS) using a panel targeting 520 cancer-relevant genes. We calculated the MATH values from NGS data and further investigated their correlation with clinical and molecular characteristics. Results: Among the 63 patients with advanced lung adenocarcinoma, the median value of MATH was 33.06. Patients with Conclusions: For patients with advanced lung adenocarcinoma, MATH may serve as a clinically practical biomarker to assess intratumor heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.